While vaccination is at the heart of the fight against the coronavirus epidemic, scientists continue to seek effective treatments for Covid-19. The Swiss pharmaceutical group Roche, in collaboration with the American laboratory Regeneron, reveals in a press release that the results of their clinical trials are promising.
The risk of hospitalizations reduced by 70%
About 25,000 patients have participated in several clinical trials. Some of them are still in progress, in particular for people hospitalized because of Covid-19. This Tuesday March 23, the pharmaceutical firm Roche informs us that a “ experimental cocktail of treatments Offers promising results, in particular the combination of two drugs: casirivimab and imdevimab. This combination therapy is used for patients who are not hospitalized. Indeed, according to Roche, the data from one of the phase III studies show a 70% decrease in hospitalizations or deaths, in individuals infected with Covid-19 and who did not require hospitalization. . In addition, the duration of symptoms also decreases by four days. It goes from 14 to 10 days, according to the lab. Treatment was given in 2400 mg and 1200 mg to high-risk patients.
Effective against variants?
In addition, Roche claims that “ this experimental treatment is the only combination of monoclonal antibodies that retains its potency against the great new variants that are emerging “. This is good news for patients, and Chief Medical Officer Levi Garraway says: “ this experimental cocktail of antibodies could therefore offer hope for a potential new therapy for high-risk patients “. The results will soon be submitted to medical experts.
